Biofrontera Inc.
BFRI
$1.54
-$0.02-1.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 19.03% | -41.03% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 19.03% | -41.03% | |||
| Cost of Revenue | 13.89% | -29.68% | |||
| Gross Profit | 20.39% | -43.45% | |||
| SG&A Expenses | -12.07% | 25.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.60% | 11.73% | |||
| Operating Income | 86.66% | -186.16% | |||
| Income Before Tax | 87.77% | -184.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 87.29% | -184.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 87.29% | -184.26% | |||
| EBIT | 86.66% | -186.16% | |||
| EBITDA | 88.15% | -183.81% | |||
| EPS Basic | 88.52% | -184.12% | |||
| Normalized Basic EPS | 88.99% | -196.03% | |||
| EPS Diluted | 88.52% | -184.12% | |||
| Normalized Diluted EPS | 88.99% | -196.03% | |||
| Average Basic Shares Outstanding | 10.62% | 0.16% | |||
| Average Diluted Shares Outstanding | 10.62% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||